| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Plaur |
| Uniprot No | Q03405 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-335aa |
| 氨基酸序列 | MGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEELELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISCGSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNGFHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGNSTHGCSSEETFLIDCRGPMNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDVQYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT |
| 预测分子量 | 36,9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Plaur(uPAR)重组蛋白的3篇参考文献示例(内容为模拟生成，实际文献需查询数据库确认)：
---
1. **文献名称**: *"Recombinant expression and functional characterization of human uPAR in cancer cell invasion"*
**作者**: Smith et al.
**摘要**: 本研究通过哺乳动物表达系统成功表达并纯化重组人源uPAR蛋白，验证其在体外促进癌细胞迁移和侵袭的功能，提示uPAR可能通过调控整合素信号通路增强肿瘤转移。
---
2. **文献名称**: *"Structural insights into the binding mechanism of Plaur with vitronectin using recombinant protein mutants"*
**作者**: Zhang et al.
**摘要**: 利用重组uPAR蛋白及其突变体进行结构分析，揭示了uPAR与胞外基质蛋白玻连蛋白(vitronectin)的关键结合域，为设计靶向uPAR的抑制剂提供了理论依据。
---
3. **文献名称**: *"Development of a high-yield E. coli system for Plaur extracellular domain production"*
**作者**: Lee & Kim
**摘要**: 报道了一种优化的大肠杆菌表达系统，高效生产可溶性uPAR胞外结构域重组蛋白，并通过质谱和表面等离子共振(SPR)验证其与配体的结合活性，为大规模制备研究级uPAR蛋白提供方法。
---
如需具体文献，建议通过PubMed或Web of Science搜索关键词 **"recombinant uPAR"** 或 **"Plaur protein expression"** 获取最新研究。
**Background of PLAUR Recombinant Protein**
PLAUR (Plasminogen Activator, Urokinase Receptor), also known as uPAR or CD87. is a glycosylphosphatidylinositol (GPI)-anchored cell surface receptor that plays a pivotal role in extracellular matrix remodeling, cell adhesion, migration, and signaling. It binds to urokinase-type plasminogen activator (uPA), facilitating the conversion of plasminogen to plasmin, a protease critical for fibrinolysis and tissue remodeling. Dysregulation of the uPA-uPAR system is implicated in pathological processes such as cancer metastasis, inflammation, and fibrosis.
Recombinant PLAUR protein is engineered using biotechnological methods to mimic the native receptor’s structure and function. Typically produced in mammalian expression systems (e.g., HEK293 or CHO cells) or bacterial hosts, the recombinant protein retains key domains for ligand binding and interaction. Its production enables detailed studies of uPAR’s biological roles, including its involvement in cancer cell invasion, angiogenesis, and immune modulation. Researchers utilize PLAUR recombinant protein to investigate mechanisms of tumor progression, screen therapeutic inhibitors, or develop diagnostic tools targeting uPAR-overexpressing cancers.
In therapeutic contexts, recombinant uPAR serves as a potential target for antibody-based therapies or small-molecule inhibitors. Its overexpression in solid tumors (e.g., breast, lung, and colorectal cancers) correlates with poor prognosis, making it a biomarker for aggressive disease. Additionally, uPAR’s role in inflammatory diseases, such as rheumatoid arthritis, highlights its broader biomedical relevance.
Despite its promise, challenges remain in optimizing recombinant uPAR stability, solubility, and post-translational modifications to ensure functional equivalence to the native protein. Advances in protein engineering and structural biology continue to refine its applications, positioning PLAUR recombinant protein as a vital tool in both basic research and translational medicine.
×
